News Sentiment

SCNI sentiment intelligence

Scinai Immunotherapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.25 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.4% over one week, -22.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Scinai Immunotherapeutics Company Profile & Introduction

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend inactive -22.3% over four weeks
Fair value -93.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 7
TradingKey 7
PR Newswire 6
dars.gov.et 4
TradingView 4
Moomoo 3
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 15
Deals and strategy 8
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Stock Titan Direct company coverage

LCK JNK 1 LLC takes 6.33% stake in Scinai Immunotherapeutics (SCNI)

LCK JNK 1 LLC has reported a 6.33% passive stake in Scinai Immunotherapeutics (SCNI), holding 317,366 American Depository Shares (ADS). Each ADS represents 4,000 ordinary shares. The filing indicates LCK JNK 1 LLC holds sole voting and dispositive power over these shares, as deta

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 13:35
Source
Stock Titan
Finviz Direct company coverage

SCNI - Scinai Immunotherapeutics Ltd ADR Latest SEC Filings

This article provides the latest SEC filing information for Scinai Immunotherapeutics Ltd ADR (SCNI), along with a comprehensive overview of its financial performance, key metrics, and market data. It covers various aspects such as market capitalization, income, sales, per-share

Tone
Negative 39/100
Event
Market update
Published
05 Jul 2026 07:40
Source
Finviz
Finviz Direct company coverage

SCNI - Scinai Immunotherapeutics Ltd ADR Options

This article provides detailed financial data and performance metrics for Scinai Immunotherapeutics Ltd ADR (SCNI). It includes key financial ratios, stock performance over various periods, insider ownership, institutional ownership, and volume data. The stock closed at $0.2408,

Tone
Negative 18/100
Event
Market update
Published
04 Jul 2026 19:42
Source
Finviz
Stock Titan Direct company coverage

Daniel Stone, RK Stone Miami adjust SCNI holdings (SCNI) after warrant exercises

Daniel Stone and RK Stone Miami, LLC have updated their holdings in Scinai Immunotherapeutics Ltd. (SCNI) following warrant exercises, as reported in an amended SCHEDULE 13G/A filing. The filing details increased sole voting power for both parties, with RK Stone Miami, LLC exerci

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:40
Source
Stock Titan
TradingView Direct company coverage

Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI)

This article provides an overview of Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), including its stock market information, financial data, and analyst estimates. It highlights that users can explore reported financial data, compare actual results with estimates, and visualize fin

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Scinai Immunotherapeutics Ltd. – NASDAQ:SCNI

This article provides the "Price to sales forward" financial metric for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI). It appears to be a stub or an incomplete data entry, as the actual value and change for the metric are not displayed. The page lists various navigation and copyr

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Scinai Immunotherapeutics Ltd. – NASDAQ:SCNI

This article provides financial information for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data display page from TradingView, indicating no available trades and offering various market d

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 08:40
Source
TradingView
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Scinai Immunotherapeutics Ltd (SCNI), noting its current valuation score is 7.47, ranking it 215 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.08, which is significantly belo

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd

This article provides a company overview for Scinai Immunotherapeutics Ltd (SCNI), including its stock performance and market capitalization. It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also

Tone
Neutral 50/100
Event
Earnings
Published
20 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Scinai Immunotherapeutics Ltd (SCNI), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their respective proportions, and historical data on institutiona

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 16:40
Source
TradingKey
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Scinai Immunotherapeutics Ltd's (SCNI) dividend history and stock split events. It notes that SCNI has distributed $0.00 in dividends over the past five years and lists several merger-type stock splits that occurred on May 6, 2024, and Novembe

Tone
Neutral 50/100
Event
Deals and strategy
Published
20 Jun 2026 15:40
Source
TradingKey
The Globe and Mail Direct company coverage

Scinai Immunotherapeutics Shareholders Approve Board Slate, Equity Expansion and Executive Awards

Scinai Immunotherapeutics shareholders approved the re-election of directors, an amendment to increase authorized ordinary shares for capital raising flexibility, and several executive and board compensation items. These approvals included amendments to CEO Amir Reichman's employ

Tone
Negative 36/100
Event
Market update
Published
20 Jun 2026 15:10
Source
The Globe and Mail
Stock Titan Direct company coverage

Scinai Immunotherapeutics (SCNI) CEO receives 400,000,000-share RSU award

Scinai Immunotherapeutics Ltd. CEO Amir Reichman was granted 400,000,000 Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026, at a price of $0.00 per share. These RSUs will vest in three equal annual installments, contingent upon his continued service. Following thi

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 18:40
Source
Stock Titan
Stock Titan Direct company coverage

Scinai Immunotherapeutics (SCNI) director awarded 120M Ordinary Share RSUs

Scinai Immunotherapeutics director Mark Germain was awarded 120 million Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026. These RSUs were granted at no cash cost and will vest in three equal annual installments, contingent on his continued service. Following this

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 18:40
Source
Stock Titan
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Scinai Immunotherapeutics Ltd (SCNI), providing a financial score of 6.87, which ranks it 197th in the Biotechnology & Medical Research industry. It notes the company's stable financial status and high operating efficiency. However, t

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no earnings forecast score is currently available for the company. It highlights that the biotechnology and medical research industry average is 8.13 for this score. The article also

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

Scinai Immunotherapeutics Ltd (SCNI) Institutional Confidence

This article provides details on the institutional confidence score for Scinai Immunotherapeutics Ltd (SCNI), highlighting its current score and changes. It lists top institutional shareholders and their recent activity, including shares held and percentage change. The data is cu

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
TradingKey
Stock Titan Direct company coverage

Scinai Immunotherapeutics (SCNI) investors approve board, share hike, RSU grants

Scinai Immunotherapeutics shareholders approved all proposals at their Annual Meeting on June 16, 2026. Key approvals included the re-election of directors, an amendment to increase the number of authorized ordinary shares, and several compensation-related items for CEO Amir Reic

Tone
Positive 64/100
Event
Market update
Published
17 Jun 2026 10:10
Source
Stock Titan
Stock Titan Direct company coverage

SCNI SEC Filings - Scinai Immunotherapeutics Ltd. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Scinai Immunotherapeutics Ltd. (SCNI) SEC filings, including annual, quarterly, and current reports, along with insider trading forms. It highlights recent filings such as the denial of a Euro 12M grant for PC111 development, a new

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

Scinai (NASDAQ: SCNI) posts Q1 2026 profit on Recipharm Israel gain

Scinai Immunotherapeutics (NASDAQ: SCNI) reported a net income of $3.6 million for Q1 2026, primarily driven by a $6.2 million non-cash bargain purchase gain from its acquisition of Recipharm Israel. Despite an operating loss of $2.5 million, the acquisition significantly strengt

Tone
Positive 63/100
Event
Deals and strategy
Published
15 Jun 2026 10:39
Source
Stock Titan
PR Newswire Direct company coverage

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Immunotherapeutics Ltd. reported its financial results for the first quarter of 2026, highlighting the acquisition of Recipharm Israel which expanded its CDMO platform and manufacturing capabilities. The company also provided a corporate update, detailing advancements in n

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Jun 2026 19:09
Source
PR Newswire
Market source Direct company coverage

Scinai Immunotherapeutics Ltd. (SCNI) stock price, news, quote and history

Scinai Immunotherapeutics Ltd. (SCNI) is a biopharmaceutical company specializing in the research and development of immune-mediated and inflammatory disease treatments, including an IL-17 NanoAb platform and PC111 for conditions like pemphigus. The company also provides contract

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jun 2026 10:09
Source
Market source
Moomoo Direct company coverage

Scinai Immunotherapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

This document is classified as a 6-K report, which is a filing submitted by foreign private issuers to the U.S. Securities and Exchange Commission (SEC) under Rules 13a-16 and 15d-16. The content of the report is simply "Document," indicating it is a placeholder or an external do

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 09:10
Source
Moomoo
Moomoo Direct company coverage

Press Release: Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai reported its first quarter 2026 financial results, emphasizing the expansion of its CDMO platform and the advancement of strategic growth initiatives. The report likely details the company's financial performance and operational developments during the quarter, reflecting

Tone
Positive 71/100
Event
Earnings
Published
11 Jun 2026 10:09
Source
Moomoo
scanx.trade Direct company coverage

Scinai reports Q1 2026 net income of $3.6 million

Scinai Immunotherapeutics Ltd reported a net income of $3.6 million for Q1 2026, a significant turnaround from a $1.6 million net loss in the previous year. This improvement was largely due to a $6.2 million bargain purchase gain from the acquisition of Recipharm Israel, which al

Tone
Positive 78/100
Event
Deals and strategy
Published
10 Jun 2026 12:39
Source
scanx.trade